Piramal Pharma Ltd

Publication & Scope

• FY2025-26 Sustainability Report published for FY2026 period.
• Covers PPS, PCC, PCH; aligned with GRI.

GHG & Environment

• FY2025-26 GHG: Scope1 47.8 Mt, Scope2 92.6 Mt (location-based), Scope3 648.8 Mt.

Governance & Board Changes

• Amit Soni joined as Non-Executive Independent Director on Feb 9, 2026.
• Amit Jain joined as Non-Executive Director (CA Alchemy representative) on May 14, 2025.

Financial & Operational Highlights

• FY2026 revenue ₹8,869 crore; PPS ₹4,915 Cr; PCC ₹2,703 Cr; PCH ₹1,274 Cr.
• Independent Directors 50% (5 of 10).

Energy & CSR Highlights

• Total workforce 6,617; 20.1% women; 30% women on board.

Energy & CSR Highlights

• 41% renewables; ₹8.98 crore CSR invested; 14.4 lakh lives reached.

Materiality & Assurance

• DNV provided limited assurance on FY2025-26 GHG data and identified 17 material topics in the Double Materiality Assessment.

Acquisition details

• Yapan Bio Private Limited, India-based CDMO for vaccines and biologics.
• Acquisition size: ₹76 crores cash for 1,46,400 equity shares; ownership rises from 33.33% to 74.00%.
• Promoter group is indirectly interested in Yapan through Piramal's investment.
• Turnover: FY2024 ₹26.91 cr; FY2025 ₹54.40 cr; FY2026 ₹26.34 cr.
• Purpose/strategy: integrate Yapan's large-molecule capabilities into Piramal's services.
• Regulatory approvals: not disclosed.
• Timeline for completion: not specified.
• Form of consideration: cash.
• Industry/sector: biopharma CDMO.
• Target incorporation: 11 October 2019.

Encumbrance Release Details

• Target Company: Piramal Pharma Limited.
• Disclosing Party: Deutsche Bank AG, Mumbai Branch (onshore); Singapore Branch (offshore); none are promoters.
• Transaction Type: Release of encumbrance over Piramal Pharma shares.
• Pre-holdings: 1,317 voting shares; 238,663,700 encumbered (17.93% capital, 18.01% voting).
• Encumbrance release: 98,400,000 shares released (7.39% cap; 7.43% voting); date 13 Aug 2026.
• Post-holdings: 140,263,700 encumbered shares (10.54% cap; 10.59% voting); 1,317 voting shares.
• Date of transaction: 13 August 2026.
• Capital context before: 1,331,348,130 equity shares; 1,325,018,448 voting shares.
• Capital context after: same as before; diluted capital unchanged.

Acquisition of additional stake in Yapan Bio

• Administrative Committee approved exercising call option to acquire 41% more equity in Yapan Bio Pvt Ltd.
• Piramal will hold ~74% of Yapan, making it a subsidiary; terms and transfer date pending.
• Final acquisition consideration and effective transfer date to be finalized; disclosures to follow upon execution.

Meeting Details

• 2 September 2026: Ashwamedh - Elara India Dialogue 2026; group/one-on-one; Mumbai.
• 17 September 2026: Jefferies 5th India Forum; group/one-on-one; Gurgaon.
• 18 September 2026: Kotak Healthcare Forum; conference; Mumbai.
• 23–24 September 2026: Goldman Sachs Global Healthcare CDMO Day; Singapore.

Filing status

• Wrapper-only submission; no substantive transcript content in this chunk.

Meeting Details

• Date: 30 July 2026; time not disclosed.
• Type/Mode: Group audio conference call.
• Organiser: Piramal Pharma Limited.

Participants

• Key participants: management roles not specified.

Purpose

• Discuss unaudited standalone and consolidated results for the quarter ended 30 June 2026.

Additional Notes

• Audio recording available on the company's website.

Meeting Details

• Event: Q1 FY2027 Earnings Conference Call; Organizer: Piramal Pharma Limited.
• Date: 30 July 2026; Time: 9:30–10:15 IST; Virtual conference call.

Purpose

• Discuss Q1 FY2027 results with investors and analysts.

Participants

• Key participants: Investor Relations & Enterprise Risk Management team.

Meeting Details

• Board meeting scheduled for 29 July 2026.

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for quarter ended 30 June 2026.

Other Notes

• Trading window closed from 1 July 2026 to 31 July 2026.

Change in shareholding

• Target: Piramal Pharma Limited.
• Disclosing party: HDFC Asset Management Company Limited for HDFC Mutual Fund schemes; non-promoter.
• Transaction Type: Disposal of shares by open-market sale.
• Pre-Transaction Holding: 9.034% (1,32,92,48,130 shares) as of 26 Jun 2025.
• Transaction Details: 2.005% disposed; open market on 14 Jul 2026.
• Post-Transaction Holding: 7.015% (9,33,93,655 diluted shares) after.
• Date of Transaction: 14 July 2026.
• Share Capital Context: Before Rs 13,29,24,81,300; After Rs 13,31,34,81,300.
• Encumbrances: None.